These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 18181526

  • 1. The solution and solid state stability and excipient compatibility of parthenolide in feverfew.
    Jin P, Madieh S, Augsburger LL.
    AAPS PharmSciTech; 2007 Dec 14; 8(4):E105. PubMed ID: 18181526
    [Abstract] [Full Text] [Related]

  • 2. The solution, solid state stability and kinetic investigation in degradation studies of lercanidipine: study of excipients compatibility of lercanidipine.
    Parmar N, Amin S, Singla N, Kohli K.
    Pharm Dev Technol; 2012 Dec 14; 17(6):730-40. PubMed ID: 21599490
    [Abstract] [Full Text] [Related]

  • 3. 5-Hydroxytryptamine-inhibiting property of Feverfew: role of parthenolide content.
    Mittra S, Datta A, Singh SK, Singh A.
    Acta Pharmacol Sin; 2000 Dec 14; 21(12):1106-14. PubMed ID: 11603284
    [Abstract] [Full Text] [Related]

  • 4. Miniaturized approach for excipient selection during the development of oral solid dosage form.
    Raijada D, Müllertz A, Cornett C, Munk T, Sonnergaard J, Rantanen J.
    J Pharm Sci; 2014 Mar 14; 103(3):900-8. PubMed ID: 24436033
    [Abstract] [Full Text] [Related]

  • 5. Parthenolide content and bioactivity of feverfew (Tanacetum parthenium (L.) Schultz-Bip.). Estimation of commercial and authenticated feverfew products.
    Heptinstall S, Awang DV, Dawson BA, Kindack D, Knight DW, May J.
    J Pharm Pharmacol; 1992 May 14; 44(5):391-5. PubMed ID: 1359053
    [Abstract] [Full Text] [Related]

  • 6. Patch test reactivity to feverfew-containing creams in feverfew-allergic patients.
    Paulsen E, Christensen LP, Fretté XC, Andersen KE.
    Contact Dermatitis; 2010 Sep 14; 63(3):146-50. PubMed ID: 20690937
    [Abstract] [Full Text] [Related]

  • 7. Selected physical and chemical properties of Feverfew (Tanacetum parthenium) extracts important for formulated product quality and performance.
    Jin P, Madieh S, Augsburger LL.
    AAPS PharmSciTech; 2008 Sep 14; 9(1):22-30. PubMed ID: 18446457
    [Abstract] [Full Text] [Related]

  • 8. Phase I dose escalation trial of feverfew with standardized doses of parthenolide in patients with cancer.
    Curry EA, Murry DJ, Yoder C, Fife K, Armstrong V, Nakshatri H, O'Connell M, Sweeney CJ.
    Invest New Drugs; 2004 Aug 14; 22(3):299-305. PubMed ID: 15122077
    [Abstract] [Full Text] [Related]

  • 9. Antiproliferative activities of parthenolide and golden feverfew extract against three human cancer cell lines.
    Wu C, Chen F, Rushing JW, Wang X, Kim HJ, Huang G, Haley-Zitlin V, He G.
    J Med Food; 2006 Aug 14; 9(1):55-61. PubMed ID: 16579729
    [Abstract] [Full Text] [Related]

  • 10. Investigating the Influence of Excipients on the Stability of Levothyroxine Sodium Pentahydrate.
    Kaur N, Suryanarayanan R.
    Mol Pharm; 2021 Jul 05; 18(7):2683-2693. PubMed ID: 34061524
    [Abstract] [Full Text] [Related]

  • 11. Intra-specific variability of feverfew: correlations between parthenolide, morphological traits and seed origin.
    Cutlan AR, Bonilla LE, Simon JE, Erwin JE.
    Planta Med; 2000 Oct 05; 66(7):612-7. PubMed ID: 11105564
    [Abstract] [Full Text] [Related]

  • 12. Variations in parthenolide content and daily dose of feverfew products.
    Nelson MH, Cobb SE, Shelton J.
    Am J Health Syst Pharm; 2002 Aug 15; 59(16):1527-31. PubMed ID: 12185827
    [Abstract] [Full Text] [Related]

  • 13. Quantification of parthenolide in Tanacetum species by LC-UV/LC-MS and microscopic comparison of Mexican/US feverfew samples.
    Avula B, Navarrete A, Joshi VC, Khan IA.
    Pharmazie; 2006 Jul 15; 61(7):590-4. PubMed ID: 16889065
    [Abstract] [Full Text] [Related]

  • 14. Biosynthesis and localization of parthenolide in glandular trichomes of feverfew (Tanacetum parthenium L. Schulz Bip.).
    Majdi M, Liu Q, Karimzadeh G, Malboobi MA, Beekwilder J, Cankar K, Vos Rd, Todorović S, Simonović A, Bouwmeester H.
    Phytochemistry; 2011 Oct 15; 72(14-15):1739-50. PubMed ID: 21620424
    [Abstract] [Full Text] [Related]

  • 15. Undesired co-amorphisation of indomethacin and arginine during combined storage at high humidity conditions.
    Petry I, Löbmann K, Grohganz H, Rades T, Leopold CS.
    Int J Pharm; 2018 Jun 10; 544(1):172-180. PubMed ID: 29669257
    [Abstract] [Full Text] [Related]

  • 16. Anti-inflammatory activity of parthenolide-depleted Feverfew (Tanacetum parthenium).
    Sur R, Martin K, Liebel F, Lyte P, Shapiro S, Southall M.
    Inflammopharmacology; 2009 Feb 10; 17(1):42-9. PubMed ID: 19112586
    [Abstract] [Full Text] [Related]

  • 17. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on human platelet activity in-vitro.
    Groenewegen WA, Heptinstall S.
    J Pharm Pharmacol; 1990 Aug 10; 42(8):553-7. PubMed ID: 1981582
    [Abstract] [Full Text] [Related]

  • 18. Influence of formulation and processing factors on stability of levothyroxine sodium pentahydrate.
    Collier JW, Shah RB, Gupta A, Sayeed V, Habib MJ, Khan MA.
    AAPS PharmSciTech; 2010 Jun 10; 11(2):818-25. PubMed ID: 20454876
    [Abstract] [Full Text] [Related]

  • 19. Compatibility of chewing gum excipients with the amino acid L-cysteine and stability of the active substance in directly compressed chewing gum formulation.
    Kartal A, Björkqvist M, Lehto VP, Juppo AM, Marvola M, Sivén M.
    J Pharm Pharmacol; 2008 Sep 10; 60(9):1131-8. PubMed ID: 18718115
    [Abstract] [Full Text] [Related]

  • 20. Surface acidity and solid-state compatibility of excipients with an acid-sensitive API: case study of atorvastatin calcium.
    Govindarajan R, Landis M, Hancock B, Gatlin LA, Suryanarayanan R, Shalaev EY.
    AAPS PharmSciTech; 2015 Apr 10; 16(2):354-63. PubMed ID: 25319055
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.